Evolus, Inc. (0K16.L)

USD 11.39

(0.03%)

EBITDA Summary of Evolus, Inc.

  • Evolus, Inc.'s latest annual EBITDA in 2023 was -41.81 Million USD , up 49.17% from previous year.
  • Evolus, Inc.'s latest quarterly EBITDA in 2024 Q2 was -4.67 Million USD , up 23.8% from previous quarter.
  • Evolus, Inc. reported an annual EBITDA of -60.72 Million USD in 2022, up 7.44% from previous year.
  • Evolus, Inc. reported an annual EBITDA of -39.05 Million USD in 2021, down -8.9% from previous year.
  • Evolus, Inc. reported a quarterly EBITDA of -4.67 Million USD for 2024 Q2, up 23.8% from previous quarter.
  • Evolus, Inc. reported a quarterly EBITDA of N/A for 2023 FY, up 49.17% from previous quarter.

Annual EBITDA Chart of Evolus, Inc. (2023 - 2015)

Historical Annual EBITDA of Evolus, Inc. (2023 - 2015)

Year EBITDA EBITDA Growth
2023 -41.81 Million USD 49.17%
2022 -60.72 Million USD 7.44%
2021 -39.05 Million USD -8.9%
2020 -144.75 Million USD 36.51%
2019 -92.1 Million USD -102.43%
2018 -46.13 Million USD -299.11%
2017 -11.5 Million USD 41.41%
2016 -19.64 Million USD 35.74%
2015 -30.56 Million USD 0.0%

Peer EBITDA Comparison of Evolus, Inc.

Name EBITDA EBITDA Difference
Editas Medicine, Inc. -163.11 Million USD 74.368%
Dynavax Technologies Corporation 9.66 Million USD 532.547%
Supernus Pharmaceuticals, Inc. 98.26 Million USD 142.55%
Perrigo Company plc 646.2 Million USD 106.47%
Illumina, Inc. -608 Million USD 93.123%
Thermo Fisher Scientific Inc. 10.8 Billion USD 100.387%
Iovance Biotherapeutics, Inc. -449.01 Million USD 90.688%
Walgreens Boots Alliance, Inc. -11.27 Billion USD 99.629%
IQVIA Holdings Inc. 3.25 Billion USD 101.284%
Heron Therapeutics, Inc. -103.79 Million USD 59.718%
Regeneron Pharmaceuticals, Inc. 4.65 Billion USD 100.898%
Unity Biotechnology, Inc. -37.28 Million USD -12.142%
Waters Corporation 1.02 Billion USD 104.09%
Biogen Inc. 2.37 Billion USD 101.759%
Sangamo Therapeutics, Inc. -87.42 Million USD 52.177%
Adicet Bio, Inc. -136.53 Million USD 69.378%
Cara Therapeutics, Inc. -117.65 Million USD 64.462%
bluebird bio, Inc. -167.16 Million USD 74.988%
Esperion Therapeutics, Inc. -150.1 Million USD 72.147%
FibroGen, Inc. -261.4 Million USD 84.006%
Agilent Technologies, Inc. 1.67 Billion USD 102.493%
Corbus Pharmaceuticals Holdings, Inc. -44.43 Million USD 5.911%
Homology Medicines, Inc. -47.75 Million USD 12.451%
Geron Corporation -174.78 Million USD 76.079%
Alnylam Pharmaceuticals, Inc. -228.12 Million USD 81.672%
Amicus Therapeutics, Inc. -92.07 Million USD 54.593%
Myriad Genetics, Inc. -67.8 Million USD 38.333%
Viking Therapeutics, Inc. -100.82 Million USD 58.533%
Intellia Therapeutics, Inc. -506.31 Million USD 91.742%
Zoetis Inc. 3.68 Billion USD 101.135%
Abeona Therapeutics Inc. -50.57 Million USD 17.326%
Mettler-Toledo International Inc. 1.16 Billion USD 103.592%
BioMarin Pharmaceutical Inc. 310.28 Million USD 113.475%
Vertex Pharmaceuticals Incorporated 4.6 Billion USD 100.908%
Kala Pharmaceuticals, Inc. -36.08 Million USD -15.875%
Ionis Pharmaceuticals, Inc. -230.01 Million USD 81.823%
Atara Biotherapeutics, Inc. -265.99 Million USD 84.282%
Verastem, Inc. -83.16 Million USD 49.727%
Nektar Therapeutics -243.1 Million USD 82.802%
Axsome Therapeutics, Inc. -224.99 Million USD 81.417%
Aclaris Therapeutics, Inc. -87.98 Million USD 52.481%
Sarepta Therapeutics, Inc. -439.19 Million USD 90.48%
OPKO Health, Inc. -65.51 Million USD 36.184%
Exelixis, Inc. 196.6 Million USD 121.266%
Neurocrine Biosciences, Inc. 416.1 Million USD 110.048%
Corcept Therapeutics Incorporated 108.32 Million USD 138.597%
Anavex Life Sciences Corp. -55.75 Million USD 25.013%
uniQure N.V. -253.1 Million USD 83.481%
Imunon, Inc. -20.78 Million USD -101.181%
Blueprint Medicines Corporation -474.61 Million USD 91.191%
Insmed Incorporated -654.73 Million USD 93.614%
Halozyme Therapeutics, Inc. 451.94 Million USD 109.251%
Agios Pharmaceuticals, Inc. -345.46 Million USD 87.897%
TG Therapeutics, Inc. 26.1 Million USD 260.192%
Incyte Corporation 919.42 Million USD 104.547%
Emergent BioSolutions Inc. -505.29 Million USD 91.726%